Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis

Details 詳細情報について

• CRID

  1361699995793301504

• DOI

  10.1007/s13311-017-0557-4

• ISSN

  18787479

• Web Site

  http://link.springer.com/article/10.1007/s13311-017-0557-4/fulltext.html

  http://link.springer.com/content/pdf/10.1007/s13311-017-0557-4.pdf

  https://api.elsevier.com/content/article/PII:S187874792301406X?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S187874792301406X?httpAccept=text/plain

• Data Source

  • Crossref